子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 脂酰辅酶A溶血心磷脂酰基转移酶1(ALCAT1)的调节剂及其用途 | CN201380009571.5 | 2013-02-15 | CN104302304A | 2015-01-21 | 玉光·施 |
| 本发明提供了脂酰辅酶A溶血心磷脂酰基转移酶1(ALCAT1)表达、功能或活性的调节剂组合物。具体地，ALCAT1的抑制剂用于治疗代谢疾病、心脏病和一般而言与线粒体功能障碍相关的疾病。提供了用于鉴定新的ALCAT1调节剂的测定。 | ||||||
| 2 | アシル補酵素Ａ：リゾカルジオリピン・アシル基転移酵素１（ＡＬＣＡＴ１）の発現、機能または活性の阻害物質を同定する方法 | JP2014557806 | 2013-02-15 | JP6253596B2 | 2017-12-27 | シー、ユーアン |
| 3 | RhoCに基づく免疫療法 | JP2015182828 | 2015-09-16 | JP6084671B2 | 2017-02-22 | マッズ ハルド アンデルセン; ペル ソル ストラテン |
| 4 | Immunotherapy based on RhoC | JP2010538345 | 2008-12-18 | JP2011506497A | 2011-03-03 | マッズ ハルド アンデルセン，; ペル ソル ストラテン， |
| The present invention relates generally to the field of prophylaxis and therapy of metastatic cancer. In particular there is provided a protein; Ras Homology gene family, member C (RhoC) or peptide fragments thereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to use of RhoC or peptides derived thereof or RhoC specific T-cells for treatment of metastatic cancer. Hence, the invention in one aspect relates to RhoC specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. Also the use of RhoC and immunogenic peptide fragments hereof in cancer treatment, diagnosis and prognosis is provided. | ||||||
| 5 | RhoC-Based Immunotherapy | US16389676 | 2019-04-19 | US20190247480A1 | 2019-08-15 | Mads Hald Andersen; Per Thor Straten |
| The present invention relates generally to the field of prophylaxis and therapy of metastatic cancer. In particular there is provided a protein; Ras Homology gene family, member C (RhoC) or peptide fragments thereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to use of RhoC or peptides derived thereof or RhoC specific T-cells for treatment of metastatic cancer. Hence, the invention in one aspect relates to RhoC specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer.Also the use of RhoC and immunogenic peptide fragments hereof in cancer treatment, diagnosis and prognosis is provided. | ||||||
| 6 | Methods and compositions for inhibition of Ras | US15508387 | 2015-09-25 | US10011600B2 | 2018-07-03 | Liansheng Li; Jun Feng; Yun Oliver Long; Pingda Ren; Yi Liu |
| Inhibitors of Ras protein, methods to modulate the activity of Ras protein, and methods of treatment of disorders mediated by Ras protein are provided. A method for regulating activity of a K-Ras, H-Ras or N-Ras mutant protein with a compound is described. Disorders that can be treated include cancer, such as hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer, or lung cancer. | ||||||
| 7 | Modulators of acyl-CoA lysocardiolipin acyltransferase 1 (ALCAT1) and uses thereof | US14378525 | 2013-02-15 | US09708411B2 | 2017-07-18 | Yuguang Shi |
| Compositions of modulators of acyl-CoA lysocardiolipin acyf transferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided. | ||||||
| 8 | Modulators of ACYL-COA Lysocardiolipin Acyltransferase 1 (ALCAT1) and Uses Thereof | US14378525 | 2013-02-15 | US20150098938A1 | 2015-04-09 | Yuguang Shi |
| Compositions of modulators of acyl-CoA lysocardiolipin acyf transferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided. | ||||||
| 9 | METHOD FOR TARGETING VASCULAR RHOJ FOR INHIBITING TUMOR ANGIOGENESIS | US14271117 | 2014-05-06 | US20140370079A1 | 2014-12-18 | Gou Young KOH; Chan Kim; Hanseul Yang; Won Do Heo; Injune Kim; Sangyong Jon; Akiyoshi Uemura |
| The present application describes a method of inhibiting tumor growth including contacting the tumor with a compound that inhibits activity of RhoJ protein. | ||||||
| 10 | PREPARATIONS AND METHODS FOR TREATING MALIGNANCIES | US14060260 | 2013-10-22 | US20140044726A1 | 2014-02-13 | Geoffrey Schmidt |
| Disclosed are therapeutic formulations comprising antibodies against the PEKRAEKIWK eptiope of the monomeric isoform of A-protein and a physiologically acceptable carrier. Methods for the treatment of subjects using these therapeutic formulations are also disclosed. | ||||||
| 11 | AAV-MEDIATED GENE THERAPY FOR RPGR X-LINKED RETINAL DEGENERATION | EP13816245.8 | 2013-01-23 | EP2872183B1 | 2018-09-26 | BELTRAN, William, A.; AGUIRRE, Gustavo, D.; JACOBSON, Samuel, G.; CIDECIYAN, Artur, V.; LEWIN, Alfred, S.; BOYE, Sanford, L.; HAUSWIRTH, William, W.; DENG, Wen-Tao |
| Described herein are methods of preventing, arresting progression of or ameliorating vision loss and other conditions associated with retinitis pigmentosa and x-linked retinitis pigmentosa in a subject. The methods include administering to a subject an effective concentration of a composition comprising a recombinant adeno-associated virus (AAV) carrying a nucleic acid sequence encoding a normal retinitis pigmentosa GTPase regulator (RPGR gene), or fragment thereof, under the control of regulatory sequences which express the product of the gene in the photoreceptor cells of the subject, and a pharmaceutically acceptable carrier. | ||||||
| 12 | MODULATORS OF ACYL-COA LYSOCARDIOLIPIN ACYLTRANSFERASE 1 ( ALCAT1) AND USES THEREOF | EP13749685.7 | 2013-02-15 | EP2822571A1 | 2015-01-14 | SHI, Yuguang |
| Compositions of modulators of acyl-CoA lysocardiolipin acyf transferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided. | ||||||
| 13 | RHOC-BASED IMMUNOTHERAPY | EP08862897.9 | 2008-12-18 | EP2234635A2 | 2010-10-06 | ANDERSEN, Mads Hald; STRATEN, Per Thor |
| The present invention relates generally to the field of prophylaxis and therapy of metastatic cancer. In particular there is provided a protein; Ras Homology gene family, member C (RhoC) or peptide fragments thereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to use of RhoC or peptides derived thereof or RhoC specific T-cells for treatment of metastatic cancer. Hence, the invention in one aspect relates to RhoC specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. Also the use of RhoC and immunogenic peptide fragments hereof in cancer treatment, diagnosis and prognosis is provided. | ||||||
| 14 | Preparations and methods for treating malignancies | US14883133 | 2015-10-14 | US09909108B2 | 2018-03-06 | Geoffrey Schmidt |
| Disclosed are therapeutic formulations comprising antibodies against the PEKRAEKIWK (SEQ ID NO:1) epitope of the monomeric isoform of A-protein and a physiologically acceptable carrier. Methods for the treatment of subjects using these therapeutic formulations are also disclosed. | ||||||
| 15 | NOVEL UBIQUITINATION SYSTEM AND THE USES THEREOF | US15478977 | 2017-04-04 | US20170283852A1 | 2017-10-05 | Zhao-Qing Luo; Jiazhang Qiu; Chittaranjan Das; Michael Sheedlo |
| An unprecedented mechanism of ubiquitination that is independent of E1 and E2 enzymes, instead relying on activation of ubiquitin by ADP-ribosylation, and which is mediated by members of the SidE effector family encoded by the bacterial pathogen Legionella pneumophila is disclosed. The herein disclosed method demonstrates a method in which ubiquitination can be carried out by a single enzyme. In addition, the present disclosure also provides compositions that may be used in ubiquitination assays and/or methods of screening active substance that may inhibit the ubiquitination process. | ||||||
| 16 | AAV-mediated gene therapy for RPGR X-linked retinal degeneration | US14413884 | 2013-01-23 | US09770491B2 | 2017-09-26 | William A Beltran; Gustavo D Aguirre; Samuel G Jacobson; Artur V Cideciyan; Alfred S Lewin; Sanford L Boye; William W Hauswirth; Wen-Tao Deng |
| Described herein are methods of preventing, arresting progression of or ameliorating vision loss and other conditions associated with retinitis pigmentosa and x-linked retinitis pigmentosa in a subject. The methods include administering to a subject an effective concentration of a composition comprising a recombinant adeno-associated virus (AAV) carrying a nucleic acid sequence encoding a normal retinitis pigmentosa GTPase regulator (RPGR gene), or fragment thereof, under the control of regulatory sequences which express the product of the gene in the photoreceptor cells of the subject, and a pharmaceutically acceptable carrier. | ||||||
| 17 | PREPARATIONS AND METHODS FOR TREATING MALIGNANCIES | US14883133 | 2015-10-14 | US20160032264A1 | 2016-02-04 | Geoffrey Schmidt |
| Disclosed are therapeutic formulations comprising antibodies against the PEKRAEKIWK (SEQ ID NO:1) epitope of the monomeric isoform of A-protein and a physiologically acceptable carrier. Methods for the treatment of subjects using these therapeutic formulations are also disclosed. | ||||||
| 18 | RhoC-based immunotherapy | US12808649 | 2008-12-18 | US09163077B2 | 2015-10-20 | Mads Hald Andersen; Per Thor Straten |
| The present invention relates generally to the field of prophylaxis and therapy of metastatic cancer. In particular there is provided a protein; Ras Homology gene family, member C (RhoC) or peptide fragments thereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to use of RhoC or peptides derived thereof or RhoC specific T-cells for treatment of metastatic cancer. Hence, the invention in one aspect relates to RhoC specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. Also the use of RhoC and immunogenic peptide fragments hereof in cancer treatment, diagnosis and prognosis is provided. | ||||||
| 19 | Optimization of Expression and Purification of Recombinant Human MxA Protein in E. Coli | US13788716 | 2013-03-07 | US20130344565A1 | 2013-12-26 | Robert W. VanDine; Robert P. Sambursky; Uma Mahesh Babu; Kyosuke Nagata |
| Full length MxA constructs and truncated MxA constructs produce human MxA protein in E. coli. The full length MxA and truncated MxA constructs are preferably E. coli codon-optimized to optimize the amount of protein made using the constructs. T5 or T7 promoters can each be used in combination with either the full length MxA or the truncated MxA constructs. In one preferred embodiment, the MxA protein produced by the full length MxA or truncated MxA constructs is used in a control prep or external control. In other preferred embodiments, the MxA protein is used as a therapeutic. | ||||||
| 20 | PEPTIDE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE | US15710696 | 2017-09-20 | US20180080926A1 | 2018-03-22 | Daria Mochly-Rosen; Gerald W. Dorn, II |
| Mitofusin modulatory peptides are described which may function as activators or inhibitors of mitochondrial fusion. The sequences and compositions comprising the sequences are useful for treating diseases or disorders associated with mitofusin 1 (Mfn1) and/or mitofusin 2 (Mfn2) and mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides for use in screening assays are also described. | ||||||
QQ群二维码
意见反馈
意见反馈